L. Mark Fisher
- Molecular Biology top 2%
- Molecular Medicine top 0.1%
- Pharmacology top 0.5%
- Epidemiology top 2%
- Infectious Diseases top 2%
- Co-authors
- Xiao-Su PanCaroline A. AustinMark OramM H O'DeaMartin GellertJane E. AmblerAlexandra AubrySandhiya Patel
- Topics
- Cancer therapeutics and mechanisms (83 papers)Antibiotic Resistance in Bacteria (33 papers)Antibiotics Pharmacokinetics and Efficacy (23 papers)
- Partner nations
- United KingdomUnited StatesItaly
In The Last Decade
L. Mark Fisher
101 papers receiving 5.4k citations
Peers
Comparison fields: 5 of 109
- Molecular Biology 3.9k
- Molecular Medicine 1.9k
- Pharmacology 1.6k
- Epidemiology 998
- Infectious Diseases 916
Countries citing papers authored by L. Mark Fisher
This map shows the geographic impact of L. Mark Fisher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Mark Fisher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Mark Fisher more than expected).
Fields of papers citing papers by L. Mark Fisher
This network shows the impact of papers produced by L. Mark Fisher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Mark Fisher. The network helps show where L. Mark Fisher may publish in the future.
Co-authorship network of co-authors of L. Mark Fisher
This figure shows the co-authorship network connecting the top 25 collaborators of L. Mark Fisher. A scholar is included among the top collaborators of L. Mark Fisher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Mark Fisher. L. Mark Fisher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 22 | |
| 3 | 28 | |
| 4 | 51 | |
| 5 | 227 | |
| 6 | 2 | |
| 7 | 12 | |
| 8 | 29 | |
| 9 | 106 | |
| 10 | 4 | |
| 11 | 22 | |
| 12 | 19 | |
| 13 | 50 | |
| 14 | Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIα (p170) and IIβ (p180) | 14 |
| 15 | 30 | |
| 16 | 98 | |
| 17 | 40 | |
| 18 | 10 | |
| 19 | 27 | |
| 20 | 7 |
About L. Mark Fisher
L. Mark Fisher is a scholar working on Molecular Medicine, Toxicology and Pharmacology, having authored 102 papers that have together received 5.6k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (83 papers), Antibiotic Resistance in Bacteria (33 papers) and Antibiotics Pharmacokinetics and Efficacy (23 papers). The work is most often cited by research in Molecular Medicine (1.9k citations), Toxicology (608 citations) and Pharmacology (1.6k citations). L. Mark Fisher has collaborated with scholars based in United Kingdom, United States and Italy. Frequent co-authors include Xiao-Su Pan, Caroline A. Austin, Mark Oram, M H O'Dea, Martin Gellert, Jane E. Ambler, Alexandra Aubry, Sandhiya Patel, Reiko Kuroda and Emmanuelle Cambau. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Nucleic Acids Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.